Ataxia Ventures

Ataxia Ventures is a specialized venture capital firm based in the United States that focuses on investing in the life sciences sector, specifically targeting treatments for ataxia and other neurodegenerative diseases. The firm actively seeks early-stage investment opportunities to help bridge the gap between laboratory discoveries and clinical applications. Notably, Ataxia Ventures co-led a $6.5 million Series Seed funding round for Goldenrod Therapeutics to advance its lead candidate, 11h, a novel brain-penetrant PDE4 inhibitor, into Phase I clinical trials for Friedreich's ataxia. Through its strategic investments, Ataxia Ventures aims to accelerate the development of disease-modifying therapies for underserved patient populations.